Merck & Co Inc
MRK
Company Profile
Business description
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. In cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 53% of the company's 2025 sales were generated from US human health (pharmaceuticals and vaccines).
Contact
126 East Lincoln Avenue
RahwayNJ07065
USAT: +1 908 740-4000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
75,000
Merck & Co Inc News & Analysis
stocks
A wave of US biotech IPOs may be starting - here’s why
M&A activity is bolstering IPOs within key areas of the biotech space. A GLP-1 maker and a protein biomarker detection company are the latest.
markets
Market Minute: Trade policy dominates, opportunities in global healthcare, and a local rate cut on the cards
Senior Portfolio Manager Bryce Anderson reviews the biggest market movements of the week, with Trump’s trade policy dominating again.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,918.70 | 18.30 | -0.20% |
| CAC 40 | 7,832.88 | 29.55 | 0.38% |
| DAX 40 | 25,277.68 | 190.41 | 0.76% |
| Dow JONES (US) | 51,850.55 | 195.60 | 0.38% |
| FTSE 100 | 10,656.28 | 104.23 | 0.99% |
| HKSE | 24,271.20 | 59.85 | 0.25% |
| NASDAQ | 27,245.90 | 120.27 | -0.44% |
| Nikkei 225 | 69,030.92 | 11.19 | -0.02% |
| NZX 50 Index | 13,791.34 | 36.28 | -0.26% |
| S&P 500 | 7,807.24 | 4.30 | -0.06% |
| S&P/ASX 200 | 8,770.00 | 13.20 | -0.15% |
| SSE Composite Index | 3,797.24 | 16.55 | -0.43% |